Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 8, 2025, reports the positive results of the GLISTEN Phase III clinical trial for linerixibat. The trial evaluated the drug's efficacy in treating cholestatic pruritus (relentless itch) in adults with primary biliary cholangitis (PBC). The data was presented as a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial outcomes and does not contain financial statements.
Material Changes and Clinical Results
The GLISTEN trial met its primary and key secondary endpoints, demonstrating significant improvements for patients treated with linerixibat compared to placebo:
- Primary Endpoint: Significant improvement in monthly itch score over 24 weeks (Least Squares mean difference: -0.72, p=0.001).
- Rapid Onset: Significant improvement observed as early as week 2 (LS mean difference: -0.71, p<0.001).
- Sleep Interference: Significant reduction in itch-related sleep interference over 24 weeks (LS mean difference: -0.53, p=0.024).
- Clinical Meaningfulness: 56% of patients in the linerixibat group achieved a clinically meaningful itch reduction (≥3-point) versus 43% in the placebo group at week 24.
- Safety Profile: Consistent with previous studies; gastrointestinal side effects were more common in the treatment group. Diarrhea was the most common adverse event, with a discontinuation rate of 4% for linerixibat versus <1% for placebo.
Guidance, Outlook, and Risks
Outlook: Linerixibat is currently not approved anywhere in the world. However, it has received orphan drug designation from both the US FDA and the European Medicines Agency for the treatment of cholestatic pruritus in PBC. Management views these results as a step toward addressing a high unmet need, as current first-line treatments for PBC do not reduce pruritus severity.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025. Specific risks include the potential for regulatory rejection despite positive trial data and the management of gastrointestinal side effects.
Key Facts for Investor Verification
- Verify the regulatory submission timeline for linerixibat following the EASL 2025 presentation.
- Confirm the commercial potential and market size for PBC treatments targeting pruritus specifically.
- Review the full safety data regarding gastrointestinal adverse events to assess long-term tolerability.
- Check for any updates on GSK's broader hepatology pipeline, including chronic hepatitis B, ALD, and MASH.
- Monitor upcoming regulatory decisions from the FDA and EMA regarding orphan drug status and potential approval pathways.